Back to Journals » Patient Preference and Adherence » Volume 4

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Authors Ebbert J, Wyatt KD, Hays JT, Klee EW, Hurt RD

Published 13 September 2010 Volume 2010:4 Pages 355—362

DOI https://doi.org/10.2147/PPA.S10620

Review by Single-blind

Peer reviewer comments 2

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, Eric W Klee, Richard D Hurt
Mayo Clinic College of Medicine, Rochester, MN, USA

Abstract: Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a public health priority. Patients achieve the greatest success when quit attempts involve behavioral therapy combined with pharmacotherapy. Varenicline is the most recent addition to the pharmacotherapeutic armamentarium for the treatment of tobacco dependence. Varenicline is efficacious and cost-effective. Smoking relapse and adverse treatment-related side effects may decrease medication adherence and patient satisfaction with varenicline. In the clinical setting, varenicline treatment can be optimized by reducing doses in patients who experience intolerable side effects, increasing the dose in partial responders, and providing long-term maintenance therapy for relapse prevention.

Keywords: varenicline, tobacco dependence, smoking cessation, nicotine addiction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]